Piper: RA data may be competitive to Alexion, but questions remain

After RA Pharmaceuticals (RARX) reported top-line results from its Phase 2 trial of zilucoplan in generalized myasthenia gravis, or gMG, Piper Jaffray analyst Christopher Raymond said the data generally looks more competitive than he would have expected. However, more details on patient background and safety are needed to make a direct comparison to Alexion’s (ALXN) Soliris, said Raymond, who thinks RA’s program is “worth monitoring.” He keeps an Overweight rating on Alexion shares, which are down 1% to $114.18 in early trading.
https://thefly.com/landingPageNews.php?id=2834671